PH1 Antibody
Description
PH1-IgG1: Human Anti-MUC1 Antibody for Cancer Therapeutics
PH1-IgG1 is a fully human immunoglobulin G1 antibody engineered to target the tumor-associated protein core of MUC1, a glycoprotein overexpressed in adenocarcinomas (e.g., breast, ovarian cancers) but minimally expressed in normal tissues .
Research Findings
-
Tumor Selectivity: PH1-IgG1 shows intense membrane/cytoplasmic staining in adenocarcinomas but only apical staining in normal tissues .
-
Affinity Enhancement: Reformatted IgG1 improved binding affinity 160-fold compared to the Fab fragment .
-
Internalization Efficiency: FITC-labeled PH1-IgG1 is rapidly internalized, a critical feature for targeted drug delivery .
-
Comparative Advantage: Unlike HMFG1 (used in phase III trials), PH1-IgG1 avoids binding normal colon MUC1, reducing off-target effects .
RL-ph1: Mouse Anti-M13 Bacteriophage Coat Protein Antibody
RL-ph1 is a mouse monoclonal IgG2b antibody targeting the major coat protein of M13 bacteriophage, widely used in molecular biology and phage display technologies .
Research Applications
-
Phage Morphogenesis Studies: Detects precursor "procoat" (23-amino-acid leader peptide) and mature coat protein .
-
Biotechnology Tool: Critical for phage display library screening and viral particle detection .
Comparative Analysis of PH1 Antibodies
| Feature | PH1-IgG1 (Anti-MUC1) | RL-ph1 (Anti-M13) |
|---|---|---|
| Species Reactivity | Human | M13 bacteriophage |
| Clinical Stage | Preclinical (cancer immunotherapy) | Research reagent |
| Key Strength | Tumor-selective internalization | High specificity for phage applications |
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Research indicates that the absence of AtPH1 function results in the mislocalization of the metal uptake transporter NRAMP1 to the vacuole. This provides a plausible explanation for the reversal of nramp3nramp4 phenotypes. PMID: 28373552
Q&A
Basic Research Questions
How to validate PH1 antibody specificity in immunohistochemistry (IHC)?
-
Perform parallel validation using knockout cell lines or tissues to confirm absence of signal .
-
Combine western blotting (WB) with IHC to verify target molecular weight and cellular localization .
-
Include isotype controls and competitive inhibition experiments with recombinant antigen .
What factors influence PH1 antibody binding affinity in physiological conditions?
-
pH-dependent binding: Antibodies engineered with histidine substitutions (e.g., H435 mutations) show altered binding at pH 5-6.5 .
-
Temperature sensitivity: Test binding kinetics at 4°C, 25°C, and 37°C using surface plasmon resonance (SPR).
-
Ionic strength: Vary buffer NaCl concentrations (50-300 mM) during ELISA validation .
How to select appropriate antibody formats for in vivo studies?
Advanced Research Challenges
How to resolve conflicting results between ELISA and flow cytometry data?
-
Epitope accessibility: Map binding regions using hydrogen-deuterium exchange mass spectrometry .
-
Conformational sensitivity: Compare native vs. denatured antigen recognition via western blot .
-
Multimerization effects: Test monomeric vs. oligomeric antigen preparations .
What strategies mitigate batch-to-batch variability in monoclonal PH1 antibodies?
-
Implement single-cell cloning with rigorous stability testing (>50 passages) .
-
Characterize glycosylation profiles using MALDI-TOF for critical lots .
-
Establish internal reference standards calibrated to WHO international units .
How to design phase 1 trials assessing PH1 antibody safety in healthy volunteers?
-
Use staggered dosing cohorts with ≥48-hour intervals between groups .
-
Monitor ferrokinetic markers (TSAT, serum iron) for ≥11 days post-administration .
What computational approaches predict PH1 antibody immunogenicity?
-
Perform molecular dynamics simulations (≥100 ns) to analyze framework flexibility .
-
Use in silico tools:
